{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:30:36Z","timestamp":1783517436663,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejmech.2021.113540","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T10:28:53Z","timestamp":1621506533000},"page":"113540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease"],"prefix":"10.1016","volume":"222","author":[{"given":"Sergio","family":"Rodriguez-Ar\u00e9valo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gri\u00f1\u00e1n-Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Vasilopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Pall\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Brocos-Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-012X","authenticated-orcid":false,"given":"Luis F.","family":"Callado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3n L.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elies","family":"Molins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-6558","authenticated-orcid":false,"given":"Steven","family":"De Jonghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-1153","authenticated-orcid":false,"given":"Dirk","family":"Daelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-7624","authenticated-orcid":false,"given":"Milica","family":"Radan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Djikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Hern\u00e1ndez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Julia","family":"Garc\u00eda-Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas A.","family":"Garc\u00eda-Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9117-8239","authenticated-orcid":false,"given":"Carmen","family":"Escolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113540_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0022-3565(25)21405-7","article-title":"Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines","volume":"230","author":"Bousquet","year":"1984","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113540_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/pr.118.016311","article-title":"Imidazoline receptor system: the past, the present, and the future","volume":"72","author":"Bousquet","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2021.113540_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pharmthera.2017.03.009","article-title":"Imidazoline I2 receptors: an update","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.113540_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archpsyc.1996.01830090049008","article-title":"Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims","volume":"53","author":"Garc\u00eda-Sevilla","year":"1996","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113540_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2014.898770","article-title":"Significance of the imidazoline receptors in toxicology","volume":"52","author":"Lowry","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113540_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2011.02.038","article-title":"Imidazoline I2 receptors: target for new analgesics?","volume":"658","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1749-6632.1999.tb09389.x","article-title":"Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved?","volume":"881","author":"Regunathan","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2021.113540_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10253890802302908","article-title":"Modulation of stress by imidazoline binding sites: implications for psychiatric disorders","volume":"12","author":"Smith","year":"2009","journal-title":"Stress"},{"key":"10.1016\/j.ejmech.2021.113540_bib9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0006-3223(93)90243-7","article-title":"Evidence of increased non-adrenoreceptor [3H]idazoxan binding sites in the frontal cortex of depressed suicide victims","volume":"34","author":"Meana","year":"1993","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.113540_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3940(93)90925-B","article-title":"Non-adrenoreceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease","volume":"160","author":"Ru\u00edz","year":"1993","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2021.113540_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0197-0186(96)00035-6","article-title":"I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease","volume":"30","author":"Gargalidis-Moudanos","year":"1997","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2021.113540_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/jnnp.2003.020446","article-title":"Imidazoline I2 receptors density increases with the malignancy of human gliomas","volume":"75","author":"Callado","year":"2004","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2021.113540_bib13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/med.20007","article-title":"Imidazoline binding sites and their ligands: an overview of the different chemical structures","volume":"24","author":"Dardonville","year":"2004","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113540_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3940(00)01625-6","article-title":"Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats","volume":"296","author":"Gilad","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2021.113540_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jcbfm.1992.7","article-title":"Reduction in focal cerebral ischemia by agents acting at imidazole receptors","volume":"12","author":"Maiese","year":"1992","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejmech.2021.113540_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1179\/174313209X444116","article-title":"Attenuation of ischemia induced rat brain injury by 2-(2-benzofuranyl)-2-imidazoline, a high selectivity ligand for imidazoline I(2)receptors","volume":"31","author":"Han","year":"2009","journal-title":"Neurol. Res."},{"key":"10.1016\/j.ejmech.2021.113540_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2009.11.063","article-title":"Reversible inhibition of intracellular calcium influx through NMDA receptors by imidazoline (I)2 receptor antagonists","volume":"629","author":"Jiang","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.joca.2019.09.002","article-title":"Efficacy and safety of the firts-in-classs imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"28","author":"Rovati","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ejmech.2021.113540_bib19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2967\/jnumed.118.208009","article-title":"Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding site in human brain","volume":"59","author":"Tyacke","year":"2018","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113540_bib20","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/brain\/awz260","article-title":"Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in\u00a0vivo 11C-BU99008 PET study","volume":"10","author":"Wilson","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2021.113540_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/acschemneuro.6b00426","article-title":"Neuroprotective effects of a structurally new family of high affinity imidazoline I2 receptors ligands","volume":"8","author":"Ab\u00e1s","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113540_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s13311-018-00681-5","article-title":"Behavioral and cognitive improvement induced by novel imidazoline I2 receptor ligands in female SAMP8 mice","volume":"16","author":"Gri\u00f1\u00e1n-Ferr\u00e9","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2021.113540_bib23","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1021\/acs.jmedchem.9b02080","article-title":"Bicyclic \u03b1-iminophosphonates as high affinity imidazoline I2 receptor ligands for alzheimer's disease","volume":"7","author":"Ab\u00e1s","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113540_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0006-8993(97)01203-1","article-title":"Immunocytochemical localization of an imidazoline receptor protein in the central nervous system","volume":"780","author":"Ruggiero","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2021.113540_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3940(98)00265-1","article-title":"Imidazoline receptor proteins in brains of patients with Alzheimer's disease","volume":"247","author":"Garc\u00eda-Sevilla","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2021.113540_bib26","first-page":"133","article-title":"Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative diseases","volume":"5","author":"Albers","year":"2000","journal-title":"J.\u00a0Neural. Transm. Suppl."},{"key":"10.1016\/j.ejmech.2021.113540_bib27","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.addr.2009.05.009","article-title":"Mitochondrial and reactive oxygen and nitrogen species in neurological disorders and stroke: therapeutic implications","volume":"61","author":"Bola\u00f1os","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2021.113540_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2525967","article-title":"Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications","volume":"2017","author":"Liu","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.ejmech.2021.113540_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0165-5728(98)00226-4","article-title":"A\u00a0central role for astrocytes in the inflammatory response to beta-amyloid: chemokines, cytokines and reactive oxygen species are produced","volume":"93","author":"Johnstone","year":"1999","journal-title":"J.\u00a0Neuroinmunol."},{"key":"10.1016\/j.ejmech.2021.113540_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.neuropharm.2010.04.005","article-title":"Oxidative stress in Alzheimer disease: a possibility for prevention","volume":"59","author":"Bonda","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2021.113540_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-2999(98)00389-6","article-title":"Characterisation and localisation of [3H]-2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors","volume":"353","author":"Lione","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11357-020-00281-2","article-title":"I2 imidazoline receptor modulation protects aged SAMP8 mice against cognitive decline by suppressing the calcineurin pathway","volume":"43","author":"Vasilopoulou","year":"2021","journal-title":"GeroScience"},{"key":"10.1016\/j.ejmech.2021.113540_bib33","series-title":"Benzofuranylimidazole Derivatives and Therapeutical Compositions Containing the Same","author":"Garc\u00eda-Sevilla","year":"1994"},{"key":"10.1016\/j.ejmech.2021.113540_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2999(95)00214-6","article-title":"LSL60101, a selective ligand for imidazoline I2 receptors, on glial fibrillary acidic protein concentration","volume":"280","author":"Alemany","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bjp.0702031","article-title":"Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands","volume":"125","author":"Boronat","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib36","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.bjp.0703485","article-title":"Induction of reactive astrocytosis and prevention of motoneuron cell death by the I2-imidazoline receptor ligand LSL60101","volume":"130","author":"Casanova","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/sj.bjp.0704579","article-title":"Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I2-site ligands, MAOIs, \u03b2-carbolines, agmatine and ibogaine","volume":"135","author":"MacInnes","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib38","series-title":"Pentacle, Version1.0.6","year":"2009"},{"key":"10.1016\/j.ejmech.2021.113540_bib39","series-title":"ADME Profiling in Drug Discovery and a New Path Paved on Silica","author":"Kr\u00fcger","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113540_bib40","unstructured":"ADMET Predictor, V. 9.5, Simulations Plus Inc., Lancaster, CA, USA. https:\/\/www.simulations-plus.com."},{"key":"10.1016\/j.ejmech.2021.113540_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small mol","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113540_bib42","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1476-5381.2012.01894.x","article-title":"Characterization of the hypothermic effects of imidazoline I2 receptor agonists in rats","volume":"166","author":"Thorn","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib43","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00210-020-02042-6","article-title":"Evaluating the effects of 2-BFI and tracizoline, two potent I2-imidazoline receptor agonists, on cognitive performance and affect in middle-aged rats","volume":"394","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2021","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol. Pharmacology"},{"key":"10.1016\/j.ejmech.2021.113540_bib44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1440-1681.1997.tb01808.x","article-title":"Effects of alpha 2-adrenoceptor antagonists and imidazoline 2-receptor ligands on neuronal damage in global ischemia in the rat","volume":"24","author":"Craven","year":"1997","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejmech.2021.113540_bib45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199702203360803","article-title":"Treatment of traumatic brain injury with moderate hypothermia","volume":"336","author":"Marion","year":"1997","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2021.113540_bib46","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1161\/01.STR.29.10.2171","article-title":"Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation","volume":"29","author":"Maier","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.ejmech.2021.113540_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neurobiolaging.2018.07.014","article-title":"Improved age-related deficits in cognitive performance and affective-like behavior following acute, but not repeated, 8-OH-DPAT treatments in rats: regulation of hippocampal FADD","volume":"71","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2018","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113540_bib48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/0269881117742667","article-title":"Repeated treatment with the \u03b12-adrenoceptor agonist UK-14304 improves cognitive performance in middle-age rats: role of hippocampal Fas-associated death domain","volume":"32","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2018","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib49","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/JPR.S132026","article-title":"Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis","volume":"10","author":"Comi","year":"2017","journal-title":"J.\u00a0Pain Res."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113540_bib50","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bph.15312","article-title":"Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer's disease","volume":"178","author":"Mirzaei","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113540_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3940(98)00265-1","article-title":"Imidazoline receptor proteins in brains of patients with Alzheimer's disease","volume":"247","author":"Garcia-Sevilla","year":"1998","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113540_bib52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113540_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WOX.0b013e3182439613","article-title":"Oxidative stress and antioxidant defense","volume":"5","author":"Birben","year":"2012","journal-title":"World Allergy Organ. J."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113540_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JIN-170032","article-title":"2-(2-benzofuranyl)-2-imidazoline (2-BFI) improved the impairments in AD rat models by inhibiting oxidative stress, inflammation and apoptosis","volume":"16","author":"Tian","year":"2017","journal-title":"J.\u00a0Integr. Neurosci."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113540_bib55","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.bbrc.2018.08.086","article-title":"Protective effect of the imidazoline I2 receptor agonist 2-BFI on oxidative cytotoxicity in astrocytes","volume":"503","author":"Choi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2021.113540_bib56","first-page":"1","article-title":"Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a Comparative study with donepezil","author":"Vasilopoulou","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113540_bib57","doi-asserted-by":"crossref","first-page":"e12781","DOI":"10.1111\/cpr.12781","article-title":"The role of astrocytes in oxidative stress of central nervous system: a mixed blessing","volume":"53","author":"Chen","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.ejmech.2021.113540_bib58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3181\/00379727-57-14776","article-title":"Estimation of the ED50 and its error by means of logarithmic-probit graph paper","volume":"57","author":"Miller","year":"1944","journal-title":"Proc. Soc. Exp. Bio. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113540_bib59","first-page":"184","article-title":"Calculation of LD50 values from the method of miller and tainter, 1944","volume":"21","author":"Randhawa","year":"2009","journal-title":"J.\u00a0Ayub Med. Coll. Abbottabad"},{"key":"10.1016\/j.ejmech.2021.113540_bib60","series-title":"MarvinSketch 5.5.1.0","year":"2011"},{"key":"10.1016\/j.ejmech.2021.113540_bib61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jcc.540100208","article-title":"Optimization of parameters for semiempirical methods I. Method","volume":"10","author":"Stewart","year":"1989","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2021.113540_bib62","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jcc.540100209","article-title":"Optimization of parameters for semiempirical methods II. Applications","volume":"10","author":"Stewart","year":"1989","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2021.113540_bib63","series-title":"AB Initio Molecular Orbital Theory","author":"Hehre","year":"1986"},{"key":"10.1016\/j.ejmech.2021.113540_bib64","series-title":"Gaussian 98 (RevisionA.7)","author":"Frisch","year":"1998"},{"key":"10.1016\/j.ejmech.2021.113540_bib65","series-title":"ChemBio3D Ultra, Version 13.0","author":"Corporation","year":"2013"},{"key":"10.1016\/j.ejmech.2021.113540_bib66","article-title":"An advanced tool for computing and handling grid-independent descriptors","author":"Duran","year":"2011","journal-title":"User Manual"},{"issue":"7","key":"10.1016\/j.ejmech.2021.113540_bib67","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2021.113540_bib68","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J.\u00a0Neurosci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421003895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421003895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:28:40Z","timestamp":1759328920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421003895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":68,"alternative-id":["S0223523421003895"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113540","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113540"}}